Breast Imaging

Should You Order Systemic Imaging for Asymptomatic Stage I Breast Cancer Surveillance?

·
Should You Order Systemic Imaging for Asymptomatic Stage I Breast Cancer Surveillance?

A 58-year-old woman, three years post-lumpectomy and radiation for Stage I estrogen receptor-positive breast cancer, arrives for her annual surveillance visit. She feels well, with no new complaints, and her physical exam is unremarkable. As you prepare to order her annual mammogram, you pause, considering whether you should also order imaging to screen for distant metastases in her chest, abdomen, or bones “just to be safe.” This is a common clinical crossroads where the desire for vigilance meets evidence-based guidelines.

For this specific scenario—an asymptomatic patient in surveillance for Stage I breast cancer—the American College of Radiology (ACR) Appropriateness Criteria rate systemic imaging studies like CT, bone scan, and PET/CT as Usually not appropriate. This article will walk through the clinical workflow and rationale behind this recommendation, explaining why less is more in this situation.

Who Fits This Clinical Scenario?

This guidance applies to a very specific patient population: individuals with a history of pathologic Stage I breast cancer who have completed definitive primary treatment (such as surgery with or without radiation and/or systemic therapy) and are now in the surveillance phase. The crucial qualifier is that the patient must be completely asymptomatic regarding potential metastatic disease. This means they have no new, persistent, and otherwise unexplained symptoms like bone pain, shortness of breath, chronic cough, abdominal pain, jaundice, or neurological changes like persistent headaches or seizures.

This workflow should not be applied to patients who:

  • Have new, concerning symptoms. A patient with new, localized bone pain, for example, would fall under a different diagnostic workup, where imaging is often appropriate.
  • Have a higher stage of disease. Patients with Stage II or III breast cancer have a higher risk of distant recurrence, and surveillance strategies may differ based on clinical guidelines and individual risk factors.
  • Are being evaluated for local recurrence. This guidance does not apply to imaging of the treated or contralateral breast. Surveillance for local recurrence is a distinct clinical question, typically addressed with annual mammography and sometimes supplemental breast ultrasound or MRI.

What Diagnoses Are You Working Up in This Scenario?

In this surveillance context, the primary goal of ordering systemic imaging would be to detect occult (asymptomatic) distant metastases. Breast cancer most commonly metastasizes to the bones, lungs, liver, and brain. The clinical question is not whether these can occur, but what the pre-test probability is of finding them in an asymptomatic Stage I survivor.

For Stage I disease, the risk of developing distant metastases is low. The rationale for not performing routine systemic imaging is rooted in this low prevalence. Extensive clinical trials and data have demonstrated that in this specific patient group, the likelihood of discovering a clinically meaningful, asymptomatic metastasis on a routine scan is exceedingly small. Therefore, the “differential diagnosis” is heavily weighted toward the patient being disease-free.

Attempting to screen for low-probability events introduces significant risks of false positives. An indeterminate lung nodule, a small liver lesion, or a focus of uptake on a bone scan are far more likely to be benign incidental findings than true metastases in this population. These findings can trigger a cascade of further, often invasive, testing, causing significant patient anxiety and potential morbidity without a proven survival benefit.

Why Is Systemic Surveillance Imaging ‘Usually Not Appropriate’ for This Scenario?

The ACR, along with other major oncology organizations like the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN), recommends against routine systemic imaging for asymptomatic Stage I breast cancer survivors. Every imaging modality intended for this purpose—from chest radiography to whole-body PET/CT—is rated Usually not appropriate. The evidence-based rationale is built on three key pillars.

First, the diagnostic yield is extremely low. The probability of detecting an isolated, asymptomatic distant metastasis in a Stage I patient is not zero, but it is low enough that the potential harms of screening outweigh the benefits. The focus of surveillance in this group should be on clinical assessment (history and physical exam) and annual mammography to detect local recurrence, which is a more common event and for which early detection is proven to be beneficial.

Second, and most critically, multiple large-scale studies have shown no improvement in overall survival. Routine imaging may detect metastases a few months earlier than if they were found due to symptoms, but this lead time has not translated into patients living longer or having a better quality of life. Treatment for metastatic breast cancer is initiated when disease is found, whether by screening or by symptoms, and outcomes have not been shown to differ based on the method of detection for this group.

Finally, the harms of over-testing are substantial. Consider these alternatives and their downsides:

  • FDG-PET/CT whole body: This study carries a significant radiation dose (☢☢☢☢ 10-30 mSv) and is prone to false positives from inflammatory or infectious processes, leading to unnecessary anxiety and biopsies.
  • CT of the chest, abdomen, and pelvis: While effective at detecting visceral disease, this also involves a notable radiation dose (☢☢☢ 1-10 mSv per section) and has a high rate of uncovering incidental findings (e.g., adrenal adenomas, simple renal cysts, benign lung nodules) that require further, often costly and stressful, workups.
  • Bone scan whole body: This modality (☢☢☢ 1-10 mSv) is sensitive but not specific. Degenerative joint disease, healing fractures, and other benign bone conditions can cause uptake that mimics metastases, requiring follow-up with other imaging.

The consensus is that the risks of radiation exposure, false positives, incidentalomas, and patient anxiety from these ‘Usually not appropriate’ studies far exceed the very small chance of benefit in this specific clinical scenario.

What’s Next? Downstream Workflow

The appropriate downstream workflow for an asymptomatic Stage I breast cancer survivor is one of active clinical surveillance, not routine imaging surveillance for distant disease.

  • If the patient remains asymptomatic: The standard of care is to continue with regular clinical follow-ups, including a thorough history and physical examination. The frequency of these visits is typically every 3-6 months for the first 3 years, then every 6-12 months for 2 years, and annually thereafter. Annual surveillance mammography of the breast(s) is the only routine imaging recommended. Patient education is key; empower the patient to report any new, persistent symptoms promptly.
  • If the patient develops new, persistent, and concerning symptoms: This changes the clinical scenario from surveillance to a diagnostic workup. At this point, imaging is indicated and should be tailored to the specific symptoms. For example:
    • New, localized bone pain warrants a workup for bone metastases, which might start with radiographs and escalate to a bone scan or MRI.
    • A new, persistent cough or dyspnea would prompt a workup for thoracic metastases, typically with chest radiography or CT.
    • New abdominal pain, elevated liver function tests, or jaundice would trigger a workup for abdominal metastases, often with an abdominal ultrasound or CT.

The core principle is to shift from a low-yield screening strategy to a high-yield diagnostic strategy, driven by clinical signs and symptoms.

Pitfalls to Avoid (and When to Get Help)

The primary pitfall in this scenario is ordering surveillance imaging out of habit, patient request, or a general sense of unease, contrary to established evidence. This can initiate a harmful and unnecessary diagnostic cascade.

Be mindful of these potential errors:

  • Misinterpreting “surveillance”: Do not conflate surveillance for local recurrence (which requires mammography) with surveillance for distant metastases (which is not recommended).
  • Dismissing vague symptoms: While routine screening is not advised, do not ignore new patient complaints. A thorough history is critical to distinguish transient aches from persistent, progressive symptoms that do require a workup.
  • Underestimating patient anxiety: Patients may request scans for reassurance. The best approach is a clear conversation explaining why clinical follow-up is the superior strategy, highlighting the risks of false positives and unnecessary radiation from scans.

If a patient presents with a constellation of symptoms that are difficult to localize or interpret, or if initial workup is unrevealing, consultation with their medical oncologist is the appropriate next step.

Related ACR Topics and Tools

Navigating imaging decisions requires access to the latest evidence and practical tools. For further reading and to explore adjacent clinical scenarios, the following resources are valuable.

Frequently Asked Questions

If a patient with Stage I breast cancer insists on getting a ‘full body scan’ for peace of mind, what should I do?

The best approach is shared decision-making. Explain the evidence from major oncology groups (ACR, ASCO, NCCN) that these scans do not improve survival for Stage I patients and carry risks like false positives, radiation exposure, and significant anxiety. Frame the conversation around maximizing benefit and minimizing harm, reinforcing that the recommended standard of care is clinical monitoring and annual mammography.

Does this ‘no imaging’ recommendation apply to patients with triple-negative or HER2-positive Stage I breast cancer?

Yes, current major guidelines generally apply this recommendation to all subtypes of Stage I breast cancer. While these subtypes can be more aggressive, the absolute risk of distant recurrence in Stage I disease remains low enough that the risk-benefit balance still disfavors routine systemic imaging in asymptomatic patients. Surveillance strategies are primarily dictated by stage, not subtype, in this context.

What about blood-based tumor markers like CA 15-3 or CA 27-29 for surveillance?

Similar to imaging, major guidelines do not recommend the routine use of serum tumor markers for surveillance in asymptomatic patients with a history of Stage I breast cancer. These markers lack sufficient sensitivity and specificity for screening, often leading to false positives and negatives, and their use has not been shown to improve outcomes.

If a patient develops a new symptom, like back pain, should I order a whole-body scan?

No, the imaging should be targeted to the symptom. If a patient develops new, persistent, localized back pain, the appropriate first step is a diagnostic workup of the spine, which might include radiographs of the painful area and potentially an MRI or bone scan. A whole-body scan is generally not the initial study of choice; the workup should be focused and symptom-driven.

How long does this recommendation against systemic imaging last? Is there a point where it’s safe to stop worrying?

The recommendation applies throughout the patient’s surveillance period as long as they remain asymptomatic. The risk of recurrence is highest in the first 2-5 years after diagnosis but never drops to zero. The principle of symptom-driven imaging, rather than routine screening, remains the standard of care indefinitely.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 29, 2026